Nuvation Bio Inc. (NUVB) financials: revenue, earnings and cash flow
Fiscal 2020–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$205M, a net margin of -325.3%; the best year in this period was 2020 with -$42M.
Over the twelve months to September 30, 2026, revenue was $202M and net income -$136M.
Free cash flow was -$181M in fiscal 2025 and positive in 0 of the 6 years shown.
The diluted share count fell 100% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $202M | $63M | $8M | $0 | — | — | — |
| Gross profit | — | — | $795000 | $0 | — | — | — |
| Operating income | -$123M | -$213M | -$593M | -$100M | -$120M | -$93M | -$44M |
| Net income | -$136M | -$205M | -$568M | -$76M | -$104M | -$87M | -$42M |
| EPS (diluted) | $-0.40 | $-0.60 | $-2.11 | $-0.35 | $-0.48 | $-0.44 | $-0.43 |
| R&D | $133M | $115M | $99M | $71M | $88M | $69M | $33M |
| Revenue growth | — | +699.0% | — | — | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$106M | -$173M | -$130M | -$68M | -$96M | -$68M | -$37M |
| Capital spending | $0 | -$8M | $0 | — | — | — | — |
| Free cash flow | -$106M | -$181M | -$130M | — | — | — | — |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — |
| Stock-based pay | $38M | $36M | $32M | $20M | $16M | $9M | $2M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | — | $529M | $503M | $611M | $661M | $765M | $216M |
| Debt | — | $57M | $9M | $4M | $4M | $3M | $4M |
| Equity | — | $306M | $464M | $605M | $655M | $746M | $215M |
| Total assets | — | $595M | $541M | $621M | $672M | $776M | $222M |
| Shares (diluted) | 352M | 342M | 269M | 219M | 217M | 198M | 97.53B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 10.1% | — | — | — | — |
| Operating margin | -61.2% | -338.7% | -7527.3% | — | — | — | — |
| Net margin | -67.4% | -325.3% | -7213.8% | — | — | — | — |
| FCF margin | -52.6% | -288.4% | -1656.5% | — | — | — | — |
| ROIC | — | -58.7% | -125.4% | -16.4% | -18.2% | -12.5% | -19.9% |
| ROE | — | -66.9% | -122.5% | -12.5% | -15.9% | -11.6% | -19.4% |
Frequently asked questions
What is Nuvation Bio’s annual revenue?
$63M in fiscal 2025 and $202M over the twelve months to September 30, 2026.
How much profit does Nuvation Bio make?
Net income was -$205M in fiscal 2025 (net margin -325.3%).
Is Nuvation Bio’s revenue growing?
Yes: revenue rose 699.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.